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Background: Collagen has proved valuable as biomedical materials for a range of clinical applications, particularly
in wound healing. It is normally produced from animal sources, such as from bovines, but concerns have emerged
over transmission of diseases. Recombinant collagens would be preferable, but are difficult to produce. Recently,
studies have shown that ‘collagens’ from bacteria, including Streptococcus pyogenes, can be produced in the
laboratory as recombinant products, and that these are biocompatible. In the present study we have established
that examples of bacterial collagens can be produced in a bioreactor with high yields providing proof of
manufacture of this important group of proteins.
Results: Production trials in shake flask cultures gave low yields of recombinant product, < 1 g/L. Increased yields,
of around 1 g/L, were obtained when the shake flask process was transferred to a stirred tank bioreactor, and the
yield was further enhanced to around 10 g/L by implementation of a high cell density fed-batch process and the
use of suitably formulated fully defined media. Similar yields were obtained with 2 different constructs, one
containing an introduced heparin binding domain. The best yields, of up to 19 g/L were obtained using this high
cell density strategy, with an extended 24 h production time.
Conclusions: These data have shown that recombinant bacterial collagen from S. pyogenes, can be produced in
sufficient yield by a scalable microbial production process to give commercially acceptable yields for broad use in
biomedical applications.
Keywords: Bacterial collagen, Recombinant protein production, Bioreactor, High cell density, pCold vector,
Defined medium, Fed-batch processBackground
Collagens are the major structural proteins in the extra-
cellular matrix of animals, including all vertebrates and
invertebrates [1,2]. Collagens are defined by a character-
istic triple-helix structure in which 3 polyproline-II-like
helices are super-coiled around a common axis to give a
rope-like structure [3]. In this structure, the only amino
acid that is small enough to fit within the centre of the
triple-helix is glycine (Gly), leading to a characteristic,
repeating amino acid sequence for the collagen triple-
helix of (Gly-Xaa-Yaa)n , where Xaa and Yaa can be any
amino acid, but are frequently proline (Pro) as Xaa and* Correspondence: John.Ramshaw@csiro.au
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reproduction in any medium, provided the or4-hydroxyproline (Hyp) as Yaa [3]. Only a limited num-
ber of Gly-Xaa-Yaa triplet sequences are found in high
frequency, while over one third of all possible triplets
have not been observed in natural sequences [4]. Those
that occur in higher frequency are often associated with
sequences that enhance the stability of the triple helix,
and include segments where hydrophobic residues or
charged pair interactions are present, as well as Hyp
containing sequences [5].
Collagen has been proven safe and effective in a wide
variety of medical products and in various clinical appli-
cations [6,7]. For medical purposes, collagen is usually
extracted from animal sources, especially bovine, but
there has been a growing concern of transmissible dis-
eases arising from use of this source. The ready availabi-
lity of a cost effective recombinant collagen would,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in developing the commercial production of human re-
combinant collagens in yeasts [8-11], with yields of
around 2 g/L being achieved in Pichia pastoris [12].
However, this system requires the co-expression of the
enzyme prolyl 4-hydroxylase (P4H) which leads to se-
condary modification of certain Pro residues to give Hyp
that contributes to collagen stability. This, in turn,
requires additional oxygenation during the fermentation
process to facilitate hydroxylation as well as the addition
of methanol for induction, adding to the complexity and
cost of production [12]. Previously, the incorporation of
Hyp in Escherichia coli cultures had been proposed,
through incorporation of Hyp in the media [13], but this
leads to non-specific incorporation into both the Xaa
and Yaa positions in the triple helix. More recently, spe-
cific incorporation of Hyp into the Yaa position in E. coli
cultures, but for only small collagen peptides, has been
reported using a biosynthetic shunt to produce ascorbate-
like entities that drive heterologously expressed P4H [14].
Collagen-like triple-helical sequences with Gly at every
third residue and a high Pro content have been observed
in various bacteria [15-17]. These bacterial collagen-like
proteins lack prolyl hydroxylation, yet several have been
shown to form stable triple-helices at 35–38°C [17],
through use of alternative stabilisation motifs [18]. These
collagen proteins can, therefore, be expressed as recom-
binant products in an E. coli system without the need
for P4H co-expression [15,18].
The bacterial collagen examined in this present study,
with its limited biological interactions behaves like a
‘blank slate’, which could be used in clinical applications
such as wound management or adhesion prevention. It
can be modified to include additional copies of the colla-
gen domain [19] or by inclusion of other mammalian
collagen sequences [20] or other triple helical proteins.
For example, it is possible to introduce specific func-
tions, such as cell binding via a mammalian integrin
binding site [21,22] or inclusion of a heparin binding do-
main [23,24] into the bacterial collagen domain.
In this study we have produced the recombinant
collagen-like protein Scl2 from S. pyogenes in E. coli using
a stirred tank bioreactor. The Scl2 sequence, including the
registration domain (V-domain), the collagen domain (CL),
but without the C-terminal non-collagen tail, was inserted
into a pColdIII (Takara Bio Inc.) vector for expression in
E. coli [18]. As an example of this new class of collagens,
the recombinant Scl2 gene construct from S. pyogenes has
previously been expressed in shake flasks [18,25]. The puri-
fied collagen protein was shown to be non-cytotoxic and
non-immunogenic, while supporting cell attachment, al-
though cell spreading was limited at 16 h [25].
If this bacterial collagen or its modified sequences are
to be used as new clinical materials, it is important thatthey can be produced in commercially feasible quantities
at a competitive cost for biomedical product manufac-
ture. This study has established that this collagen can be
produced in good yield in a bioreactor using a cost ef-
fective fully defined medium.
Results and discussion
Protein expression constructs
In the present study, recombinant bacterial collagen,
VCL, has been expressed using the pCold vector system,
as it had previously been shown that this system was ef-
fective in shaker culture for production of the protein in
the E .coli host strain BL21 [18,25]. The construct was
termed VCL, where V is the non-triple-helical registra-
tion domain and CL is the triple-helical, collagen-like
domain (Figure 1). The pCold vectors selectively induce
target protein synthesis at low temperatures where the
synthesis of host proteins is reduced or suppressed and
protease activity is decreased. The pCold system is
designed for efficient protein expression utilising a pro-
moter derived from the cspA gene, which is a cold-shock
gene, with a lac operator inserted downstream to control
expression [26]. In addition, expression of a second con-
struct, VCLH, which included a heparin binding domain,
H, substituted using site directed mutagenesis into the
CL sequence, was also tested. In this construct, a heparin
binding sequence, GRPGKRGKQGQK, derived from the
collagenous tail of acetylcholine esterase [23,24] was sub-
stituted via PCR directed integration into the CL sequence
GPAGPMGPAGER that starts at base pair 564/amino acid
residue 188 (Figure 1). The substitution was confirmed by
DNA sequencing. The pCold vector system is available as
a research tool; it is possible that proprietary commercial
vectors could give much better yields than observed in the
present study that has used the pCold system. Recombi-
nant proteins, VCL and VCLH, were isolated in sufficient
quantities for use as electrophoretic quantitation stan-
dards (Figure 2A) using a conventional purification proto-
col (Ni metal affinity column chromatography and with
binding via a His6 tag incorporated at the N-terminus of
the protein). Final purification was achieved by gel per-
meation chromatography [25].
Protein expression in shake flasks
The expression of VCL in shake flasks using 2xYT
Media and Defined Media (DM) were used as the base-
line process for this study. Cells were grown for 24 h at
37°C, after which an OD600 nm of around 6 was achieved,
prior to induction at 25°C. Expressed protein production
was determined after incubation at 25°C for 10 h, fol-
lowed by a further 14 h at 15°C. It was hoped that the
additional reduction in temperature would maintain the
selective target protein production achieved by the
pCold vector system. The changes in cell densities were
Figure 1 Schematic diagrams showing the VCL and VCLH constructs. Base pair numbers are indicated below the schematics. The His-Tag
and Enzyme Site domains have been added to the naturally occurring S. pyogenes Scl2.28 gene [15] as previously described [25].
Figure 2 SDS-PAGE analysis of protein expression. (A) Protein
expression in shake flask cultures. MW, molecular weight standards;
DM, defined medium; YT, complex medium (2xYT) and purified VCL
protein standards 0.7 to 2.0 μg. (B) Protein expression time course,
fed-batch process with stepwise temperature reduction after
induction. MW, molecular weight standards; I, pre-induction; I + 1 to
I + 24 hours after induction; VCL, purified VCL standard.
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end of the production phase, moderate amounts of wet
cell paste, 8.3 g/L for DM and 9.7 g/L for 2xYT, were
obtained. Expression yields were determined by com-
parison to known amounts of VCL protein by SDS-
PAGE (Figure 2A). These shake flask processes achieved
recombinant collagen expression levels of around 0.2 g/L
in DM and 0.3 g/L in 2xYT (Table 1). These yields are
adequate for biochemical and biophysical studies of VCL
and related constructs such as VCLH, but are well below
production levels required for commercial production.Protein expression in 2 L stirred tanks – batch process
(low cell density)
Expression of both the VCL and the VCLH was tested
using a batch process in a 2 L stirred tank bioreactor.
After inoculation, both processes were maintained at 37°C
for the first 5 hours to increase the cell density prior to in-
duction. After this initial period, the culture had an optical
density OD600 nm in the range of 2 to 3. The cultures were
then cooled to 25°C, induced with IPTG and incubated
for a further 7 h. For both constructs, wet cell paste yields
were between 5 and 6 g/L. The increase in cell density
was tracked throughout (Figure 3A), showing, steady
increases in both cases. The final optical densities were
below those achieved in shake flasks reflecting the shorter
times for both the growth and induction phases in the
bioreactor experiments. Despite the shorter incubation
times, both trials led to moderate recombinant collagen
yields, 0.7 to 1.0 g/L. Transfer of the process to a more
controlled bioreactor resulted in a 3-fold increase in total
collagen production and a 4-fold increase in specific
productivity (mass of collagen per cell), although further
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Figure 3 Effect of fermentation process design and induction
temperature on growth of collagen-producing E. coli strains.
Cell concentration was estimated by measuring optical density at
600 nm. See Table 1 for experimental details. (A) Shake flask and
low cell density processes.♦, VCL, shake flask, complex medium
(2xYT);▲, VCL, shake flask, defined medium; ■, VCL, bioreactor
batch process (low cell density); ●, VCLH, bioreactor batch process
(low cell density). (B) High cell density processes. ♦, VCLH, bioreactor
fed-batch process, induction at 25°C for 10 hours; ▲, VCL, bioreactor
fed-batch process, induction at 25°C for 10 hours; ●, VCL, bioreactor
fed-batch process, induction at 15°C for 24 hours; ■, VCL, bioreactor
fed-batch process, induction for 24 hours with stepwise temperature
reduction.
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(high cell density)
Both the VCL and VCLH constructs were used for initial
testing of expression using a high cell density, fed-batch
process. A high cell density process was implemented to
increase collagen production. If the specific collagen
productivity (mass of collagen per cell) can be main-
tained then an increase in cell density will result in an
increase in collagen production. To achieve a high cell
density prior to induction, the initial growth phase was
extended to 24 h during which cell densities typicallyexceeding OD600 nm of 80 were obtained. Again, the
temperature was reduced to 25°C and recombinant pro-
tein expression induced by the addition of IPTG; the
culture was incubated for a further 10 h. The process
resulted in a significant improvement in collagen yields;
8.2 g/L for VCLH and 9.5 g/L for VCL, indicating that
this fermentation approach has potential for high level
production of the recombinant protein. The specific
productivity was less compared to the low cell density
process but due to the large increase in cell mass the
volumetric productivity increased almost 10-fold. As the
differences between VCL and VCLH production were
relatively small, only VCL was used for further process
optimisation.
The previous experiment showed that a 12°C
temperature decrease resulted in collagen yields in ex-
cess of 8 g/L. The effect of induction temperature was
examined further by following a similar protocol, except
the induction was changed from 25°C to 15°C and the
induction time was increased from 10 to 24 h. This
process was used to test whether a lower temperature
would further reduce host cell protein production
resulting in greater enrichment of recombinant colla-
gen. The lower induction temperature did result in
greater enrichment of the target protein (the specific
productivity increased 2-fold) whilst volumetric produc-
tion was similar to the previous experiment (9.5 g/L at
25°C and 10 g/L at 15°C). The final optical density was
lower at 15°C (OD600 nm= 65) compared to 25°C
(OD600 nm= 88) despite the induction time being
increased from 10 to 24 hours. The unchanged volu-
metric production was most likely the result of slower
cell growth at the lower temperature as shown in
Figure 3B; cell growth is negligible after reducing the
temperature to 15°C.
To further increase recombinant collagen production
the extended induction time was retained and stepwise
temperature reduction was introduced into the process
to enhance pCold’s “cold shock selectivity”. After induc-
tion for 10 h at 25°C, the temperature was reduced to
20°C and the culture held at this temperature for 5 h.
The temperature was then reduced again to 15°C and
held at this temperature for a further 9 h. This process
change resulted in a further marked yield increase with
recombinant collagen production levels of 13.0, 19.0 and
19.3 g/L in three separate batches (average of 17.1 g/L) –
production levels that are potentially within a commer-
cially feasible range. The stepwise temperature reduction
resulted in an increase in final optical density without too
greater impact on specific productivity. Recombinant col-
lagen production was followed during the induction phase
of the process using SDS-PAGE (Figure 2B) which shows
a steady increase in VCL production during the initial
hours after induction with a further increase at the end of
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aliquots, for use as gel standards, also showed that the col-
lagen domains of the expressed products were resistant to
trypsin digestion [19] indicating that the collagen domains
had folded into the triple-helical conformation which con-
fers proteolytic resistance [19].
In the present study, we have shown that good produc-
tion levels of VCL can be achieved, with a maximum pro-
duction of 19.3 g/L. After removal of the His6 tag and the
V-domain, which would probably be necessary for bio-
medical applications of the collagen-like domain, this
equates to a maximum yield of the CL domain of about
14.1 g/L, with a further loss of yield depending on the effi-
ciency of any purification protocol. The use of the His6 tag
is efficient for laboratory purifications [19,25], but would
not be suitable for large scale commercial preparations.
Other affinity approaches may be more useful and cost
effective, including the use of specific collagen binding
proteins [27]. The present study has shown that excel-
lent recombinant collagen yields can be obtained using
a high cell density fed-batch process using pCold vec-
tors. The best yields obtained compare favourably with
the average yields reported for other bacterial expres-
sion studies of 14 g/L [28], although there may be
higher commercial yields that remain commercial-in-confidence. Nevertheless, use of alternative vector sys-
tems that may be better suited for use at high cell den-
sities may lead to even further increases in yield. The
present yield, however, compares favourably with fed-
batch fermentation yields obtained using P. pastoris and
Hansenula polymorpha. These recombinant systems
were used to produce a 30 kDa fragment containing an
N-propeptide which after cleavage gives a 14 kDa mam-
malian collagen fragment in the yeasts P. pastoris and
Hansenula polymorpha (recently designated as a Pichia
species) [10]. These data gave the best yield with H. poly-
morpha expression of around 0.6 g/L, well below the bac-
terial collagen yields achieved in this study. Nevertheless,
much better yields, better than 2 g/L, could be obtained
from P. pastoris when used in commercially optimised
production [12].
Conclusions
An initial optimisation approach of the present pCold
vector system showed that recombinant bacterial colla-
gen can be produced in large quantities in E. coli, with
average production levels of 17.1 g/L, much greater than
has been achieved for mammalian collagens in yeast ex-
pression systems [12]. This was achieved at low cost
through use of a fully defined medium, which was
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the introduction of any media components that could
have a negative impact on downstream processing. The
bacterial production system was not affected by the
introduction of a heparin binding sequence, with com-
parable yields being obtained for both the VCL and
VCLH constructs.
Bacterial collagen is an excellent alternative source of
collagen for use in biomaterial applications and as a
scaffold for tissue engineering. As a bacterially expressed
product, it can be made as a non-animal collagen in an
animal free system. As an expressed product, it does not
have the variation in quality, purity and predictability of
performance that can be found for animal derived mate-
rials, nor does it carry the risk of transmission of infec-
tious agents. The properties of the bacterial collagen
from S. pyogenes have been characterised [25]. It has
been shown that this bacterial collagen is biocompatible,
non-cytotoxic and non-immunogenic [25] and hence
suitable for biomaterial applications. This collagen is
stable without the need for secondary modifications, es-
pecially proline hydroxylation. The bacterial collagen
system also allows for the design of novel functional
materials, such as the inclusion of selected binding
domains, eg: introducing integrin binding domains [22]
or heparin binding into the natural bacterial collagen
sequence.Methods
Recombinant construct
The fragment of S. pyogenes Scl2.28 gene [15] encoding
the globular (V) and the collagen-like (CL) domains, and
the variations to include a His-tag at the N-terminal of the
V-domain and an enzyme cleavage site between the V-
and CL domains, was cloned into the pColdIII vector
(Takara Bio, Shiga, Japan), giving construct VCL, and
transformed for expression in E. coli strain BL21 as pre-
viously described [25]. In addition, the construct was
cloned into the shuttle vector pSL1180 using restriction
sites 50 NdeI and 30 BamHI. This clone was used for site
directed mutagenesis to introduce a heparin binding se-
quence [23,24] GRPGKRGKQGQK at base pair 564 via
PCR directed integration, giving construct VCLH. PCR
products were treated with DpnI, to digest all parental
DNA and subsequently transformed into E. coli strain
XL1-BLUE. Selected DNA clones were sequenced and
those containing the required heparin binding domain
was subcloned into pColdIII vector (Takara Bio, Shiga,
Japan) using the 50 NdeI and 30 BamHI sites. Positive
clones were selected and transformed into E. coli host
BL21 for expression. Schematics of the two constructs are
shown in Figure 1. Prior to expression studies, all con-
structs were confirmed by DNA sequencing.Media
Complex medium (2xYT) contained 16 g tryptone, 10 g
yeast extract and 5 g NaCl per litre. The defined
medium (DM) used in this study contained per litre:
KH2PO4, 10.6 g; (NH4)2HPO4, 4.0 g; citric acid, 1.7 g;
glucose, 25 g; MgSO4.7H2O, 1.23 g; ampicillin, 200 mg;
thiamine hydrochloride, 4.4 mg; and trace salts solution
5 mL. The trace salts solution contained per litre:
CuSO4.5H2O, 2.0 g; NaI, 0.08 g; MnSO4.H2O, 3.0 g;
Na2MoO4.2H2O, 0.2 g; boric acid, 0.02 g; CoCl2.6H2O,
0.5 g; ZnCl2, 7.0 g; FeSO4.7H2O, 22.0 g; CaSO4.2H2O,
0.5 g and H2SO4, 1 mL. As required, glucose, magne-
sium, trace salts, thiamine and ampicillin were aseptic-
ally added as concentrated stock solutions to the media
after sterilisation.
Seed cultures
Primary seed cultures were prepared from single col-
onies taken from a fresh transformation plate, and
grown in 10 mL of 2xYT (in a 30 mL bottle) containing
10 g/L glucose and 200 μg/mL ampicillin. The culture
was incubated at 37°C shaking at 200 rpm for 24 h. A
volume (0.5 mL) of the primary seed culture was used to
inoculate 500 mL of 2xYT (in a 2L Erlenmeyer flask)
containing 10 g/L glucose and 200 μg/mL ampicillin.
This secondary seed culture was incubated at 37°C sha-
king at 200 rpm for 16 h.
Protein expression in shake flasks
Cultures were grown in 2 L Erlenmeyer flasks containing
500 mL of either 2xYT or DM media and incubated at
37°C for 24 h. The cultures were then cooled to 25°C
and protein expression induced by addition of 0.5 mM
isopropyl beta-D-thiogalactopyranoside (IPTG). The cul-
tures were then incubated at 25°C for 10 h and for a fur-
ther 14 h at 15°C. Samples were taken during the course
of the incubation and the cells pelleted by centrifugation
followed by disruption using Bugbuster™ (Merck) and
quantification by SDS-PAGE (as described below).
Protein expression in 2L stirred tanks
Recombinant bacterial collagens were produced in 2 L
stirred tank bioreactors connected to a Biostat B (Sarto-
rius Stedim Germany) control system. The initial volume
of medium in the fermenter was 1.6 L and glucose as
used as the carbon source. A volume of the secondary
seed culture was added to the bioreactor to attain an ini-
tial optical density (measured at 600 nm) of 0.25. Foam-
ing was controlled via the automatic addition of 10%
(v/v) polypropylene glycol 2025; 3 mL of the antifoam
solution was added prior to inoculation. The pH setpoint
was 7.0, controlled by automatic addition of either 10%
(v/v) H3PO4 or 10% (v/v) NH3 solutions. The dissolved
oxygen setpoint was 20% of saturation and a two-step
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above the specified setpoint. The agitator speed ranged
from 500 rpm to 1200 rpm and airflow (supplemented
with 5% pure O2) ranged from 0.3 L min
-1 to 1.5 L
min-1. For the high cell density fed-batch processes, the
feed solution was comprised of 400 mL of 660 g/L glu-
cose solution to which 40 mL of 1 M MgSO47H2O
added. The feed flow rate was 15 mL h-1 and the feed
was initiated 8.5 h after inoculation. Incubation times
and temperatures for individual experiments are given in
Table 1. The culture was cooled (over a 20 minute
period) to the required temperature 24 h after inocula-
tion to activate the cold shock component of the vector
and protein expression induced by addition of 1 mM
(final concentration in the culture) IPTG.
Preparation of protein standards
Recombinant VCL and VCLH protein standards were
extracted from wet cell paste by sonication in 40 mM
sodium phosphate buffer, pH8.0, 1 mM phenylmethane-
sulfonyl fluoride, using 20 ml buffer per gram of cell
paste. After centrifugation, clarified supernatant was
taken to 20 mM sodium phosphate 300 mM NaCl and
30 mM imidazole buffer, pH8.5, and absorbed onto a Ni
charged HyperCel-Sepharose metal ion affinity resin
(Pall Life Sciences). Elution was by the same buffer, but
containing 500 mM imidazole. Eluted fractions contain-
ing recombinant protein were pooled, concentrated and
exchanged into 20 mM sodium phosphate buffer, pH8.0,
using a 10 kDa cross-flow filtration membrane (Pall Life
Sciences), followed by further purification in the same
buffer on a Sephacryl S200 26/60 column (GE Health-
care). After additional treatment of purified VCL and
VCLH with trypsin [19], SDS-PAGE [29] as described
for Sample Analysis, was used to show that the triple
helix remained intact.
Sample analyses
Samples were taken from the cultures throughout each
process. Cell mass was determined by measuring the op-
tical density of diluted samples at 600 nm (OD600 nm).
VCL or VCLH were quantified in small sub-samples and
to correct for changes in cell numbers, the formula 200/
OD600 nm was used to determine the volume of culture
required for SDS PAGE analysis. The aliquot was centri-
fuged and the cell pellet lysed by addition of 40 μL of
Bugbuster™ (Merck) and incubated for 1 h. After the in-
cubation, 10 μL 5x sample buffer containing 5% (v/v) 2-
mercaptoethanol was added to the lysate and the mixture
heated at 95°C for 1 min prior to electrophoresis. SDS
PAGE was completed as described by [29] using
NuPAGE (Invitrogen) 4-12% Bis-Tris gels with MES
running gel buffer, at 180 V for 60 min, followed by
staining with Coomassie Blue R-250. After destaining,the band corresponding to VCL or VCLH bands were
quantified by densitometric analysis using Multi Gauge
V3.0 FujiFilm software and compared to known stand-
ard loadings of purified VCL protein.
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